The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor
Abstract
BACKGROUND AND OBJECTIVE: There is a clinical need for new oral anticoagulants to prevent and treat thromboembolic diseases. Given its integral role in the coagulation cascade, factor Xa is a particularly promising target for new anticoagulation therapies. The aim of this study was to investigate the safety, pharmacodynamics, and pharmacokinetics of BAY 59--7939, an oral, direct factor Xa inhibitor. METHODS: This single-center, randomized, single-blinded, placebo-controlled, dose-escalation study included 108 healthy white male subjects aged 19 to 45 years. Subjects received single oral doses of either BAY 59--7939 (1.25--80 mg) or placebo; in addition, 1 group received 2 doses of BAY 59--7939 (5--mg tablet and oral solution) or placebo in a crossover design. RESULTS: Oral BAY 59--7939 in single doses up to 80 mg was safe and well tolerated and was not associated with an increased risk of bleeding compared with placebo. Pharmacodynamic effects (inhibition of factor Xa activity, prothrombin time, activated partial thromboplastin time, and Hep Test) and plasma concentration profiles were dose-dependent. Maximum inhibition of factor Xa activity was achieved 1 to 4 hours after administration of BAY 59--7939 and ranged from 20% to 61% for the 5- to 80-mg doses. BAY 59--7939 selectively inhibited factor Xa activity; thrombin (factor IIa) and antithrombin were unaffected. Inhibition of factor Xa activity and prolongation of prothrombin time correlated well with BAY 59--7939 plasma concentrations (r=0.949 and 0.935, respectively). CONCLUSIONS: BAY 59--7939 was well tolerated with predictable pharmacodynamics and pharmacokinetics across a wide range of doses in healthy male subjects. BAY 59--7939 was shown to be an effective and specific factor Xa inhibitor.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of Venous Thromboembolism
Geerts, W. H., Pineo, G. F., Heit, J. A., Bergqvist, D., Lassen, M. R., Colwell, C. W., & Ray, J. G. (2004) · Chest · doi:10.1378/chest.126.3_suppl.338s · Cited by 5,895
Ethical principles for medical research involving human subjects
(2003) · Manual for Research Ethics Committees · doi:10.1017/cbo9780511550089.027 · Cited by 2,585
The Epidemiology of Venous Thromboembolism
White, R. H. (2003) · Circulation · doi:10.1161/01.cir.0000078468.11849.66 · Cited by 2,310
American Heart Association/American College of Cardiology Foundation Guide to Warfarin Therapy
Hirsh, J., Fuster, V., Ansell, J., & Halperin, J. L. (2003) · Circulation · doi:10.1161/01.cir.0000063575.17904.4e · Cited by 911
Hirsh, J., & Levine, M. (1992) · Blood · doi:10.1182/blood.v79.1.1.bloodjournal7911 · Cited by 894
Bauer, K. A., Eriksson, B. I., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011099 · Cited by 666
Eriksson, B. I., Bauer, K. A., Lassen, M. R., & Turpie, A. G. G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011100 · Cited by 631
Antithrombotic Therapy in Atrial Fibrillation
Singer, D. E., Albers, G. W., Dalen, J. E., Go, A. S., Halperin, J. L., & Manning, W. J. (2004) · Chest · doi:10.1378/chest.126.3_suppl.429s · Cited by 547
COFACTOR PROTEINS IN THE ASSEMBLY AND EXPRESSION OF BLOOD CLOTTING ENZYME COMPLEXES
Mann, K. G., Jenny, R. J., & Krishnaswamy, S. (1988) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.57.070188.004411 · Cited by 536
Savi, P., Chong, B. H., Greinacher, A., Gruel, Y., Kelton, J. G., Warkentin, T. E., Eichler, P., Meuleman, D., Petitou, M., Herault, J.-P., et al. (2005) · Blood · doi:10.1182/blood-2004-05-2010 · Cited by 212
Cited by
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Steffel, J., Verhamme, P., Potpara, T. S., Albaladejo, P., Antz, M., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy136 · Cited by 2,123
Ageno, W., Gallus, A. S., Wittkowsky, A., Crowther, M., Hylek, E. M., & Palareti, G. (2012) · Chest · doi:10.1378/chest.11-2292 · Cited by 1,503
Rivaroxaban versus Enoxaparin for Thromboprophylaxis after Hip Arthroplasty
Eriksson, B. I., Borris, L. C., Friedman, R. J., Haas, S., Huisman, M. V., Kakkar, A. K., Bandel, T. J., Beckmann, H., Muehlhofer, E., Misselwitz, F., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800374 · Cited by 1,433
Steffel, J., Collins, R., Antz, M., Cornu, P., Desteghe, L., Haeusler, K. G., Oldgren, J., Reinecke, H., Roldan-Schilling, V., Rowell, N., et al. (2021) · EP Europace · doi:10.1093/europace/euab065 · Cited by 1,132
Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa Inhibitors
Connolly, S. J., Milling, T. J., Eikelboom, J. W., Gibson, C. M., Curnutte, J. T., Gold, A., Bronson, M. D., Lu, G., Conley, P. B., Verhamme, P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607887 · Cited by 807
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Self-citationClinical Pharmacokinetic and Pharmacodynamic Profile of Rivaroxaban
Mueck, W., Stampfuss, J., Kubitza, D., & Becka, M. (2014) · Clinical Pharmacokinetics · doi:10.1007/s40262-013-0100-7 · Cited by 612
Self-citationFox, K. A. A., Piccini, J. P., Wojdyla, D., Becker, R. C., Halperin, J. L., Nessel, C. C., Paolini, J. F., Hankey, G. J., Mahaffey, K. W., Patel, M. R., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr342 · Cited by 608
“While rivaroxaban is predominantly metabolized by the liver, approximately one-third is cleared renally.(24) In patients with moderate renal insufficiency (CrCl 30–49 mL/min), there is a moderate but relevant effect on rivaroxaban exposure; maximal serum concentrations are 25–30% higher(14) and pharmacokinetic models…”
BackgroundEriksson, B. I., Quinlan, D. J., & Weitz, J. I. (2009) · Clinical Pharmacokinetics · doi:10.2165/0003088-200948010-00001 · Cited by 522
Zhao, P., Zhang, L., Grillo, J. A., Liu, Q., Bullock, J. M., Moon, Y. J., Song, P., Brar, S. S., Madabushi, R., Wu, T. C., et al. (2011) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2010.298 · Cited by 522
Ogata, K., Mendell‐Harary, J., Tachibana, M., Masumoto, H., Oguma, T., Kojima, M., & Kunitada, S. (2010) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009351883 · Cited by 453
Laboratory Measurement of the Anticoagulant Activity of the Non–Vitamin K Oral Anticoagulants
Cuker, A., Siegal, D. M., Crowther, M. A., & Garcia, D. A. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.05.065 · Cited by 449
Assessment of laboratory assays to measure rivaroxaban – an oral, direct factor Xa inhibitor
Martinoli, J.-L., LeFlem, L., Guinet, C., Plu-Bureau, G., Depasse, F., Perzborn, E., & Samama, M. M. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-03-0176 · Cited by 449
Kubitza, D., Becka, M., Mueck, W., Halabi, A., Maatouk, H., Klause, N., Lufft, V., Wand, D. D., Philipp, T., & Bruck, H. (2010) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2010.03753.x · Cited by 432
Self-citationCohen, H., Hunt, B. J., Efthymiou, M., Arachchillage, D. R. J., Mackie, I. J., Clawson, S., Sylvestre, Y., Machin, S. J., Bertolaccini, M. L., Ruiz-Castellano, M., et al. (2016) · The Lancet Haematology · doi:10.1016/s2352-3026(16)30079-5 · Cited by 410
Mekaj, A., Mekaj, Y., Duci, S., & Miftari, E. (2015) · Therapeutics and Clinical Risk Management · doi:10.2147/tcrm.s84210 · Cited by 407
Mueck, W., Kubitza, D., & Becka, M. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12075 · Cited by 371
Self-citationWang, Z., Frost, C., Shenker, A., & Barrett, Y. C. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-05-0328 · Cited by 356
Buller, H. R., Lensing, A. W. A., Prins, M. H., Agnelli, G., Cohen, A., Gallus, A. S., Misselwitz, F., Raskob, G., Schellong, S., & Segers, A. (2008) · Blood · doi:10.1182/blood-2008-05-160143 · Cited by 342
Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants
Samuelson, B. T., Cuker, A., Siegal, D. M., Crowther, M., & Garcia, D. A. (2017) · Chest · doi:10.1016/j.chest.2016.08.1462 · Cited by 345
Agnelli, G., Gallus, A., Goldhaber, S. Z., Haas, S., Huisman, M. V., Hull, R. D., Kakkar, A. K., Misselwitz, F., & Schellong, S. (2007) · Circulation · doi:10.1161/circulationaha.106.668020 · Cited by 337
Eriksson, B. I., Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Muehlhofer, E., Dierig, C., Misselwitz, F., & Kälebo, P. (2006) · Circulation · doi:10.1161/circulationaha.106.642074 · Cited by 335
Kubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006296058 · Cited by 334
Self-citationMueck, W., Lensing, A. W. A., Agnelli, G., Decousus, H., Prandoni, P., & Misselwitz, F. (2011) · Clinical Pharmacokinetics · doi:10.2165/11595320-000000000-00000 · Cited by 327
ERIKSSON, B. I., BORRIS, L., DAHL, O. E., HAAS, S., HUISMAN, M. V., KAKKAR, A. K., MISSELWITZ, F., & KÄLEBO, P. (2006) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01657.x · Cited by 302
The discovery and development of rivaroxaban, an oral, direct factor Xa inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., & Misselwitz, F. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3185 · Cited by 297
Self-citationEffects of the oral, direct factor Xa inhibitor rivaroxaban on commonly used coagulation assays
HILLARP, A., BAGHAEI, F., FAGERBERG BLIXTER, I., GUSTAFSSON, K. M., STIGENDAL, L., STEN‐LINDER, M., STRANDBERG, K., & LINDAHL, T. L. (2011) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2010.04098.x · Cited by 288
Prins, M. H., Lensing, A. W. A., Brighton, T. A., Lyons, R. M., Rehm, J., Trajanovic, M., Davidson, B. L., Beyer-Westendorf, J., Pap, Á. F., Berkowitz, S. D., et al. (2014) · The Lancet Haematology · doi:10.1016/s2352-3026(14)70018-3 · Cited by 283
Rivaroxaban: A New Oral Factor Xa Inhibitor
Perzborn, E., Roehrig, S., Straub, A., Kubitza, D., Mueck, W., & Laux, V. (2010) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.110.202978 · Cited by 276
Self-citationBorris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Kälebo, P., Muelhofer, E., Misselwitz, F., Eriksson, B. I., & Mueck, W. (2008) · Thrombosis and Haemostasis · doi:10.1160/th07-12-0714 · Cited by 273
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802361499 · Cited by 268
Self-citationKubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2006) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006286904 · Cited by 254
Self-citationLefebvre, P., Coleman, C. I., Bookhart, B. K., Wang, S.-T., Mody, S. H., Tran, K. N., Zhuo, D. Y., Huynh, L., & Nutescu, E. A. (2014) · Journal of Medical Economics · doi:10.3111/13696998.2013.858634 · Cited by 66
Weeda, E. R., Kohn, C. G., Peacock, W. F., Fermann, G. J., Crivera, C., Schein, J. R., & Coleman, C. I. (2016) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1828 · Cited by 15
Metadata
- Authors
- KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2005-10
- Volume
- 78
- Issue
- 4
- Pages
- 412-421
- ISSN
- 0009-9236 (ISSN-L)
- OpenAlex
- W2045987573
- Cited by
- 649
- References
- 18
- FWCI
- 9.28
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.